GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Maia Biotechnology MAIA · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.09

+2.83%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Maia Biotechnology

From its filings with the US Securities and Exchange Commission

SEC filings

Maia Biotechnology is based in Chicago, Illinois and is incorporated in Delaware. Its shares trade on NYSE under the ticker MAIA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Jul 2022
Employees
18
Head office
444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Vlad VitocChairman of the Board, President, Chief Executive Officer, Co-Founder, since 2018$1.4m
  • Mr. Jeffrey HimmelreichPrincipal Financial and Accounting Officer, Head of Finance$338,374
  • Dr. Sergei GryaznovChief Scientific Officer$929,838
  • Dr. Stan SmithLead Independent Director, since 2022$75,000
  • Mr. Steven ChaoukiIndependent Director$60,000
  • Mr. Ramiro GuerreroIndependent Director$60,000
  • Mr. Cristian LuputIndependent Director$60,000
  • Mr. Jean-Manasse TheageneIndependent Director$60,000
  • Ms. Ngar YeeIndependent Director, since 2024$90,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Maia Biotechnology focuses on clinical stage oncology drug candidates targeting difficult-to-treat cancers.
  • THIO is a first-in-class telomere-targeting agent in Phase II clinical study for Non-Small Cell Lung Cancer.
  • The company has a second-generation pipeline with five compounds for improved cancer cell specificity and anticancer activity.

Weaknesses

  • The company employs only 18 full-time employees, which may limit operational capacity.
  • Maia Biotechnology is a clinical stage company with no approved therapies yet on the market.
  • The firm's pipeline includes only two main drug candidates, THIO and Libtayo, with limited diversity.

Opportunities

  • The growing global market for oncology therapies presents significant expansion potential.
  • Advancing THIO in Phase II clinical trials could lead to regulatory approval and market entry.
  • The second-generation pipeline offers potential for new telomere-targeting agents with improved efficacy.

Threats

  • Competition from established biotechnology firms in the oncology sector remains a challenge.
  • Regulatory hurdles and clinical trial failures could delay product development timelines.
  • The company's limited workforce may hinder rapid response to market changes or unexpected challenges.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.